Cipher Pharma Q3 revenue up 24% on higher Natroba sales

Cipher Pharmaceuticals

06/11/2025 22:11

Overview

Cipher Q3 2025 revenue grows 24% yr/yr but misses analyst expectations

Adjusted EBITDA for Q3 2025 beats estimates, rising 79% yr/yr

Company repaid $12 mln in debt and repurchased $1.6 mln in shares in Q3 2025

Outlook

Cipher aims to grow Natroba's market share in the U.S. anti-parasitic market

Company seeks Health Canada approval for Natroba to enter Canadian market

Cipher plans to out-license Natroba globally in regions with high unmet need

Result Drivers

NATROBA SALES - Natroba product revenue increased by $2.6 mln or 47% in Q3 2025, contributing significantly to overall revenue growth

CASH GENERATION - Strong cash generation with $10.8 mln cash from operations in Q3 2025, aiding in debt repayment and share repurchases

DEBT REPAYMENT - Company repaid $12 mln in debt during Q3 2025, further de-levering post quarter end with additional $5 mln repayment

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$12.80 mln
$13.52 mln (4 Analysts)
Q3 EPS
$0.21
Q3 Net Income
$5.50 mln
Q3 Adjusted EBITDA
Beat
$7.32 mln
$6.64 mln (4 Analysts)
Q3 EBITDA
$6.30 mln


Press Release: ID:nCNWFFK2za

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)